April 01, 2022 | Featured
April 1st, 2022
London, April 01, 2022 – Intract Pharma, an innovative oral protein delivery company, today announced the appointment of Dr Vipul Yadav as Chief Executive Officer of the company, effective April 1st, 2022. Dr Yadav, who has been serving as the Director of Research for over 5 years, also joins Intract Board of Directors. Dr Bill Lindsay who co-founded and led Intract since incorporation in 2015 will remain with the company as Director of Business Development.
On the appointment, Bill Lindsay said “It is with great satisfaction that I hand over management of Intract to Dr Yadav, who has been a major driving force in development of the company to date, in particular in pioneering our biotherapeutics development platform, Soteria”.
Dr Yadav said ‘’I am excited to transition into this role at such a critical junction of the company’s journey towards progressing its oral protein technology platform into clinical development with multiple pharma partners. I would like to thank the current management and board for entrusting me with this role and I look forward to working alongside the Intract board, management, and R&D staff to lead the company to the next phase of growth and realise the potential of our innovative technologies’’.
Dr Vipul Yadav joined Intract following completion of his PhD and since then has served as the Director of Research. During his tenure the company advanced into the oral biologic delivery space for treatment of gastrointestinal and systemic immunoinflammatory diseases and established multiple pharma partnerships to advance the technology deeper into preclinical with early and late-stage biologic candidates.
Dr Yadav received his PhD from University College London, School of Pharmacy working in the lab of Intract founder Prof Abdul Basit where he researched gastrointestinal stability and tissue uptake mechanisms involved in oral delivery of peptides and monoclonal antibodies.
Copyright © 2018 Intract Pharma
A site by: Web Design London